Integra Lifesciences Holdings (IART) Liabilities and Shareholders Equity (2009 - 2026)

Integra Lifesciences Holdings has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $3.6 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 2.85% year-over-year to $3.6 billion; the TTM figure through Jun 2026 stood at $14.4 billion (down 9.06% YoY), while the FY2025 annual figure was $3.6 billion, down 10.78% from the prior year.
• Liabilities and Shareholders Equity came in at $3.6 billion for Q2 2026 at Integra Lifesciences Holdings, roughly flat from $3.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $4.1 billion in Q1 2024 to a low of $3.6 billion in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $3.8 billion, with a median of $3.8 billion recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity advanced 8.97% in 2024 and declined 11.72% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $3.9 billion in 2022, then declined by 2.77% to $3.8 billion in 2023, then climbed by 6.75% to $4.0 billion in 2024, then decreased by 10.78% to $3.6 billion in 2025, then retreated by 1.07% to $3.6 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $3.6 billion in Q2 2026, $3.6 billion in Q1 2026, and $3.6 billion in Q4 2025.